Are you Dr. Fox?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 40 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
400 East Jamie Court
Myokardia, Inc., Ste 102
South San Francisco, CA 94080Phone+1 650-741-0902- Is this information wrong?
Summary
- Dr. Jonathan Fox, MD is a cardiologist in South San Francisco, California. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993- Duke University HospitalResidency, Internal Medicine, 1987 - 1990
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 1993 - 2016
Clinical Trials
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- 13 citationsUse of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping ReviewKhalil Anchouche, Malik Elharram, Emily Oulousian, Amir Razaghizad, Robert Avram, Guillaume Marquis-Gravel, Varinder K. Randhawa, Richard Nkulikiyinka, Wei Ni, Mona Fi...> ;The Canadian Journal of Cardiology. 2021 Jul 10
- 15 citationsPatient and Family Experience With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN) Amyloidosis: Results of Two Focus GroupsDavid Rintell, Dena Heath, Florencia Braga Mendendez, Elizabeth Cross, Theodore P. Cross, Vincent Knobel, Bruno Gagnon, Cameron W. Turtle, Alan Cohen, Edward Kalmykov,...> ;Orphanet Journal of Rare Diseases. 2021 Feb 8
- 47 citationsStabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac AmyloidosisGraham Lohrmann, Alexandra Pipilas, Roberta Mussinelli, Deepa M. Gopal, John L. Berk, Lawreen H. Connors, Nirupama Vellanki, Jennifer Hellawell, Omar K. Siddiqi, Jonat...> ;Journal of Cardiac Failure. 2020 Sep 1
- Join now to see all
Press Mentions
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid CardiomyopathyNovember 11th, 2018
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis CardiomyopathyMay 3rd, 2018
Professional Memberships
- Member
